(Q38068514)

28 August 2017

1 reference

title

RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence (English)

1 reference

28 August 2017

0 references

Alessandra Lugaresi

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

20 December 2012

1 reference

Expert Opinion on Drug Delivery

28 August 2017

published in

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

273-283

1 reference

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

The role of glatiramer acetate in the early treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Factors that influence adherence with disease-modifying therapy in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Patient satisfaction with an injection device for multiple sclerosis treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

A new electronic device for subcutaneous injection of IFN-β-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Easypod: a new electronic injection device for growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Subcutaneous interferon-beta-1a : new formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2013.746311

10.1517/17425247.2013.746311

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference